Peptide mapping quantifies modification at individual sites, but the same site-level results can correspond to different distributions across intact molecules.
- Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
- Is Your Supply Chain Ready For The End Of Class VI?
- When Lyophilization Fails At Scale, First Scrutinize Your Formulation
- The 5 Shifts That Could Remake Lyophilization By 2040
- Your 7 Decisions To Make Before MES Configuration
- DEA Reveals Hidden Costs Of Analytical Validation Guidelines
- Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
GUEST COLUMNISTS
-
Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
Geopolitical shocks are reshaping outsourced pharmaceutical testing. Learn how procurement teams can strengthen resilience and protect continuity.
-
Is Your Supply Chain Ready For The End Of Class VI?
Revisions to USP <87> and <88> update biological reactivity testing — changes that are especially important for companies that rely on single-use technology.
-
When Lyophilization Fails At Scale, First Scrutinize Your Formulation
When lyophilizing a challenging biologic drug product, use an integrated approach optimizing formulation and process parameters together.
-
The 5 Shifts That Could Remake Lyophilization By 2040
Purdue University-based LyoHUB charts a risk-based course to modernizing freeze-drying technology for better performance and advanced modalities.
-
Your 7 Decisions To Make Before MES Configuration
Don't wait until manufacturing execution system (MES) configuration to answer these 7 questions. Define your manufacturing process before digitizing it.
-
DEA Reveals Hidden Costs Of Analytical Validation Guidelines
By treating distinct validation guidelines as decision-making units, data envelopment analysis (DEA) allows for the mathematical evaluation of their resource efficiency.
-
Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
Systemic vulnerabilities exist in thermal uniformity assurance, steam penetration verification, regulatory fragmentation, and tech harmonization.
BIOSIMILAR WHITE PAPERS
-
High-Performing Ionizable Lipids For Controlled Nucleic Acid Delivery
Ionizable lipids are central to effective mRNA delivery, influencing potency, biodistribution, and toxicity. See why advancing delivery beyond the liver will require stronger structure-function insights.
-
Unlocking The Full Potential Of Antibody-Drug Conjugates (ADCs)6/15/2026
ADCs are evolving rapidly. Gain insight into how success now hinges on managing complexity, delivery, and scalability to turn promising designs into viable therapeutic products.
-
Aseptic Process Design And Simulation Under Annex 1 Guidelines1/9/2026
Gain insight into how Annex 1 reshapes aseptic process validation, as well as into risk reduction by design and why isolators are redefining modern sterile manufacturing standards.
-
A Risk-Based Approach To Plasmid DNA And mRNA Process Development9/23/2025
Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.
-
A Shift Towards Biofluorescent Particle Counters In Manufacturing5/12/2025
Sterility in injectable drug manufacturing is vital for patient safety and efficiency. Discover how biofluorescent particle counters revolutionize contamination control, regulatory compliance, and operational excellence in modern pharma.
-
A Comprehensive Solution For Adventitious Agent Testing2/13/2026
Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.
BIOSIMILAR APP NOTES & CASE STUDIES
- Oligonucleotide Purification And Synthesis
- Don't Intensify Blindly: Preventing Fouling And Restoring Performance With Targeted Cleaning Of Protein A Resins
- Assessing Particle Generation In A Single-Use Mixing System
- Optimizing TFF And SPTFF For High-Concentration mAb Formulations
- Mild pH Protein A Purification Step With A Mild Elution Resin
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Waltz Health And Fresenius Kabi Expand Direct Access To Biosimilars Through Waltz Connect Platform
- Adalvo Expands Biosimilars Portfolio Through Acquisition Of Romiplostim Biosimilar Programme From Enzene
- FDA Approves Lucamzi – Biosimilar To Lucentis
- BioSim Proposes Incorporating Measures Into Electoral Programs To Promote Biosimilar Medicines
- Bio-Thera Announces NMPA Approval Of BAT2306, The First Secukinumab Biosimilar Approved In China
- Samsung Bioepis Releases Fourth Quarter 2026 Biosimilar Market Report Highlighting Importance Of Supply Continuity
- Celltrion Healthcare Canada Ltd. Announces The Opening Of A New Office In Montreal, Strengthening Its Growing Presence In Quebec
- Formycon And Biocelys Combine Complementary Development And Manufacturing Expertise In New Biosimilar Project FYB286
NEWSLETTER ARCHIVE
- 10.29.26 -- How Indian Biosimilar Companies Are Poised To Succeed
- 10.27.26 -- Reduce Bioprocessing Supply Risk With Manufacturing Closer To You
- 10.22.26 -- Reduce risk. Move Annex 1 forward.
- 10.22.26 -- FDA Modernizes Container Closure Guidance: What Is Changing
- 10.21.26 -- A Sustainable Future: Leveraging 3Rs To Innovate And Accelerate In Testing
